- 2020’s United States Presidential election night was a potential tipping point for easing regulations on psychoactive drugs.
- In clinical studies, psilocybin has been shown to be effective in treating mental health issues such as depression, anxiety, obsessive-compulsive disorder, post-traumatic stress disorder, and eating disorders.
- Compass Pathways plc is a pharma company developing a psilocybin-based drug and therapy pairing, COMP360, for treatment-resistant depression.
- After its initial public offering in September, Compass became the first psychedelic company to publicly trade on United States markets.
- Compass Pathways plc has surged since its initial public offering, however, there are serious questions about its valuation and drug candidate.
For further details see:
Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront